Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Cogent Biosciences, Inc.
M.D. Anderson Cancer Center
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest